Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to $1.8 million.

  • Enanta Pharmaceuticals' Other Accumulated Expenses fell 4169.1% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 4169.1%. This contributed to the annual value of $1.8 million for FY2025, which is 4169.1% down from last year.
  • As of Q3 2025, Enanta Pharmaceuticals' Other Accumulated Expenses stood at $1.8 million, which was down 4169.1% from $2.4 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' Other Accumulated Expenses' 5-year high stood at $14.4 million during Q1 2022, with a 5-year trough of $1.5 million in Q1 2024.
  • Its 5-year average for Other Accumulated Expenses is $5.0 million, with a median of $5.4 million in 2023.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first soared by 14413.19% in 2021, then crashed by 7157.99% in 2024.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' Other Accumulated Expenses stood at $6.4 million in 2021, then rose by 6.44% to $6.9 million in 2022, then tumbled by 45.98% to $3.7 million in 2023, then decreased by 18.64% to $3.0 million in 2024, then tumbled by 40.32% to $1.8 million in 2025.
  • Its last three reported values are $1.8 million in Q3 2025, $2.4 million for Q2 2025, and $1.6 million during Q1 2025.